NCT04225871

Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis

← Hub

Registry fields

Overall status: COMPLETED
Conditions: Generalized Myasthenia Gravis
Study type: INTERVENTIONAL
Phase: PHASE3
Primary purpose: TREATMENT
Intervention type: DRUG
Interventions: zilucoplan (RA101495)
Lead sponsor: UCB Biopharma SRL (INDUSTRY)

Cached at: 2026-08-12 22:59:29

View on ClinicalTrials.gov

Brief summary

The RAISE-XT study is an open-label extension study to evaluate the long-term efficacy, safety, and tolerability of zilucoplan in subjects with gMG who have previously participated in a qualifying Ra Pharmaceuticals sponsored zilucoplan study.

Contact

Need a report or Korean medical writing based on this trial?

Request a report Medical writing Custom research report